Ampligen Chronic Fatigue Syndrome Data May Be Sufficient For FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is reviewing Hemispherx’s reanalysis of data from its Ampligen Phase III trial to determine if an additional confirmatory study is necessary.